Diabetes Care Publishes Results From Prevalence Phase Of Corcept’S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

ReutersApr 21, 2025 12:17 PM

April 21 (Reuters) - Corcept Therapeutics Inc CORT.O:

DIABETES CARE PUBLISHES RESULTS FROM PREVALENCE PHASE OF CORCEPT’S CATALYST TRIAL IN PEOPLE WITH DIFFICULT-TO-CONTROL TYPE 2 DIABETES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

TradingKey - As investors shift gears from solid performance from US equity for yet another year, focus is turning to predictions on performance for the Vanguard ETF in 2026 relative to overall market performance.

Nvidia Stock: Breaking Down Its Key Risk and Why It’s Still a Compelling Buy in 2026

TradingKey - The semiconductor sector has been experiencing a massive rally recently, with Nvidia reaching an all-time high in terms of stock price. As of April 27, this chip manufacturer's market cap is now above $5 trillion with an impressive financial performance for its year ended 1-25-2026. Dur

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

Palantir reports Q1 2026 earnings May 4 after close. Consensus: $1.54B revenue, $0.28 EPS. Polymarket 96% beat odds. Triangle breakout targets $153–$165. Buy or wait?

VOO Stock Price: Is the S&P 500 ETF Still the Smarter Buy vs QQQ?

TradingKey - All eyes are on the VOO stock price as investors contemplate whether broad-market stability or tech-heavy growth provides a better path to 2026.

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?

TradingKey - An athleisure company, Lululemon Athletica（LULU）, has built a very successful niche in the fashionable athletic wear category.

Featured Tools